홈 > 시장보고서 > 의약품 > 암

시장보고서

상품코드

1290434

세계의 혈액암 치료제 시장(2023-2030년)

Global Blood Cancer Drugs Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

세계의 혈액암 치료제 시장 규모는 2022년 630억 달러에 달하며, 2030년에는 최대 1,135억 달러에 달할 것으로 예상됩니다. 혈액암 치료제 시장은 2023-2030년의 예측 기간 중 7.8%의 CAGR을 보일 것으로 예상됩니다. 주요 시장 동향은 면역 요법의 급속한 발전입니다.

예를 들어 2023년 4월, 보다 스마트하고 조기 암 치료를 가능하게 하는 차세대 정밀 종양학 기업 스트라타 종양학(Strata Oncology, Inc.)는 진행성 암 환자를 위한 세계 최초의 분자 프로파일링 검사 '스트라타 셀렉트(Strata Select)'를 출시할 것이라고 발표했습니다.

이 새로운 진단 테스트는 항 PD-1/PD-L1 체크포인트 억제제 면역치료 효과에 대한 새로운 다변량 예측 바이오마커 알고리즘인 '면역치료 반응 점수(Immunotherapy Response Score)'를 갖추고 있습니다. 혈액암 치료제는 화학요법, 분자표적치료제, 면역요법, 지지요법 등 혈액 및 골수 내 암세포를 특이적으로 표적화하여 증식을 억제하는 것을 목표로 하는 다양한 치료법을 포함합니다.

이러한 약물은 비정상적인 세포 과정을 파괴하고, 암세포의 성장을 억제하고, 세포 사멸을 유도하고, 정상적인 혈액 세포의 생산과 기능을 회복시키는 것을 목표로합니다.

혈액암 치료제 시장은 혈액암 유병률 증가, 암 연구 발전, 표적치료제, 면역치료제, 맞춤의료 개발 등의 요인에 의해 주도되고 있습니다.

예를 들어 2023년 5월 Amneal Pharmaceuticals, Inc.는 Neulasta의 바이오시밀러인 FYLNETRA를 1회용 주사기 형태로 출시할 예정이라고 발표했습니다. 호중구감소증 치료에 사용됩니다.

시장 역학

혈액암 증가

혈액암의 유병률 증가는 예측 기간 중 시장 점유율을 높이는 주요 요인입니다. 혈액암, 특히 백혈병, 림프종, 다발성 골수종과 같은 특정 유형의 암은 노년층에서 더 많이 진단됩니다. 세계 인구의 고령화가 진행됨에 따라 혈액암 발생률은 전반적으로 증가하고 있습니다.

특정 환경 요인에 노출되거나 건강에 해로운 생활습관을 선택하면 혈액암 발병 위험이 높아질 수 있습니다. 환경적 요인에는 방사선, 특정 화학물질, 살충제, 산업 오염물질에 대한 노출이 포함됩니다. 또한 흡연, 과도한 음주, 좌식 생활과 같은 건강에 해로운 행동도 혈액암 발병에 영향을 미칠 수 있습니다.

높은 치료비용과 부작용

혈액암 치료제는 연구개발에 많은 노력을 기울이고, 제조 및 시험 과정이 복잡하기 때문에 비용이 많이 드는 경우가 많습니다. 이러한 약품의 비용은 환자, 의료 시스템 및 지불자에게 큰 경제적 부담을 줄 수 있습니다. 치료비 상승은 시장 성장에 영향을 미치고 혈액암 치료제에 대한 환자의 접근성을 저해할 수 있습니다.

혈액암 치료제는 피로, 메스꺼움, 구토, 탈모, 면역 억제, 장기 독성 등 다양한 부작용을 유발할 수 있습니다. 이러한 부작용은 환자의 삶의 질과 치료 순응도에 큰 영향을 미칠 수 있습니다. 부작용을 개척하고 지지요법을 개발하는 것은 환자의 결과를 개선하고 혈액암 치료제를 시장에 출시하는 데 있으며, 중요한 고려사항입니다.

COVID-19의 영향 분석

COVID-19 팬데믹은 혈액암 치료제 시장을 포함한 헬스케어 산업에 큰 영향을 미쳤습니다. 혈액암 환자는 면역력이 약하고 COVID-19로 인한 심각한 결과의 위험이 높기 때문에 취약한 것으로 알려져 있습니다. 이에 따라 환자 관리 전략은 바이러스에 대한 노출을 최소화하는 방향으로 변경되고 있습니다.

혈액암 치료제와 관련된 일부 연구 활동은 일시적으로 우선순위가 낮아지거나 COVID-19 관련 프로젝트로 방향이 전환될 수 있습니다. 이러한 연구 초점의 전환은 혈액암 치료제 시장의 의약품 개발 및 기술 혁신 속도에 영향을 미칠 수 있습니다.

러시아·우크라이나 분쟁 분석

러시아·우크라이나 분쟁은 혈액암 치료제 시장에 큰 영향을 미치고 있습니다. 이 분쟁으로 인해 연구기관과 제약회사의 연구개발 공동작업이 중단될 수 있습니다. 신약 개발, 임상시험 및 과학 교류의 공동 작업이 방해되어 새로운 혈액암 치료제의 혁신과 개발 속도에 영향을 미칠 수 있습니다.

러시아와 우크라이나의 분쟁은 혈액암 치료제 시장의 국제 협력과 투자에 영향을 미칠 수 있습니다. 기업과 투자자들은 지정학적 위험과 불확실성으로 인해 이들 시장에 신중하게 접근하고 있으며, 이는 투자 및 공동연구의 둔화로 이어질 수 있습니다.

Market Overview

The Global Blood Cancer Drugs Market size reached US$ 63 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 113.5 billion by 2030. The Global Blood Cancer Drugs Market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. The key market trend is the rapid advancements of immunotherapies.

For instance, in April 2023, Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer.

The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Blood cancer drugs encompass diverse therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies, and supportive care medications, designed to specifically target and inhibit the growth of cancerous cells in the blood and bone marrow.

These drugs aim to disrupt abnormal cellular processes, suppress cancer cell proliferation, induce apoptosis, and restore normal blood cell production and function.

The blood cancer drugs market is driven by factors such as the increasing prevalence of blood cancers, advancements in cancer research, development of targeted therapies, immunotherapies, and personalized medicine.

For instance, in May 2023, Amneal Pharmaceuticals, Inc. announced the commercial launch of FYLNETRA, a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy.

Market Dynamics

Increasing prevalence of blood cancers

The increasing prevalence of blood cancers is the major factor driving the market share during the forecast period. Blood cancers, particularly certain types such as leukemia, lymphoma, and multiple myeloma, are more commonly diagnosed in older individuals. As the global population continues to age, the overall incidence of blood cancers increases.

Exposure to certain environmental factors and unhealthy lifestyle choices can increase the risk of developing blood cancers. Environmental factors include exposure to radiation, certain chemicals, pesticides, and industrial pollutants. Unhealthy behaviors like smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to the development of blood cancers.

High cost and side effects of treatment

Blood cancer drugs often come with a high price tag due to the extensive research and development efforts involved and the complexity of manufacturing and testing processes. The cost of these drugs can pose a significant financial burden on patients, healthcare systems, and payers. The high cost of treatment can impact market growth and hinder patient access to blood cancer drugs.

Blood cancer drugs can cause various adverse effects, including fatigue, nausea, vomiting, hair loss, immunosuppression, and organ toxicity. These side effects can significantly impact patients' quality of life and treatment adherence. Managing side effects and developing supportive care measures are important considerations in improving patient outcomes and market acceptance of blood cancer drugs.

COVID-19 Impact Analysis

The COVID-19 pandemic has profoundly impacted the healthcare industry, including the blood cancer drugs market. Blood cancer patients are considered vulnerable due to their compromised immune systems and higher risk of severe COVID-19 outcomes. As a result, patient management strategies have been modified to minimize exposure to the virus.

Some research activities related to blood cancer drugs may have been temporarily deprioritized or redirected towards COVID-19-related projects. This shift in research focus may impact the pace of drug development and innovation in the blood cancer drugs market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has significantly impacted the blood cancer drugs market. The conflict may disrupt research and development collaboration in institutions and pharmaceutical companies. Collaborative efforts in drug discovery, clinical trials, and scientific exchange may be hampered, impacting the pace of innovation and development of new blood cancer drugs.

The conflict between Russia and Ukraine may impact international collaborations and investments in the blood cancer drugs market. Companies and investors may approach these markets with caution due to geopolitical risks and uncertainties, potentially leading to a slowdown in investments and collaborations.

Segment Analysis

The Global Blood Cancer Drugs Market is segmented based on cancer type, therapy type, route of administration, End User, and region.

Based on cancer type, the leukemia segment is expected to dominate the market share

The leukemia market will hold 35.8% of the global blood cancer drugs market share in 2022. Leukemia has been the subject of extensive research and development efforts in the field of blood cancer drugs. Significant advancements have been made in understanding the molecular basis of different leukemia subtypes, leading to the development of targeted therapies and immunotherapies.

For instance, in May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older.

Geographical Analysis

North America holds the largest market share due to the presence of key players and advanced healthcare infrastructure

North America holds the 41.3% market share for the blood cancer drugs market in 2022 due to the presence of key players and advanced healthcare infrastructure in the region. North America boasts advanced healthcare infrastructure, including well-established hospitals, research institutions, and oncology centers.

The region has a robust healthcare system that facilitates access to diagnosis, treatment, and follow-up care for blood cancer patients. The availability of state-of-the-art medical facilities, advanced diagnostic technologies, and specialized healthcare professionals supports the demand for blood cancer drugs and drives market growth.

Competitive Landscape

The major global players in the market include: Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.

Why Purchase the Report?

To visualize the Global Blood Cancer Drugs Market segmentation based on cancer type, therapy type, route of administration, End User, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of blood cancer drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Blood Cancer Drugs Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Cancer Type
3.2. Snippet by Therapy Type
3.3. Snippet by Route of Administration
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing prevalence of blood cancers
  - 4.1.1.2. Development of targeted therapies and immunotherapies
- 4.1.2. Restraints
  - 4.1.2.1. High cost of treatment
  - 4.1.2.2. Side effects associated with treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Advancements in cancer research
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Cancer Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Leukemia*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Myeloma
7.4. Non-Hodgkin Lymphoma
7.5. Hodgkin Lymphoma

8. By Therapy Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 8.1.2. Market Attractiveness Index, By Therapy Type
8.2. Chemotherapy*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiation Therapy
8.4. Immunotherapy
8.5. Targeted Therapy
8.6. Others

9. By Route of Administration

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Ambulatory Surgical Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. The U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Amgen Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. AstraZeneca Plc
13.3. Takeda Pharmaceutical Company Ltd
13.4. Bayer AG
13.5. Celgene Corporation
13.6. Eli Lilly
13.7. Bristol-Myers Squibb Company
13.8. Gilead Sciences Inc.
13.9. Daiichi Sankyo Company Ltd
13.10. UCB SA

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,294,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 7,017,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,358,000

※ 부가세 별도